The next major wave of treatment options for multiple diseases is cell therapies, and Gaithersburg-based MaxCyte is one of the companies driving this revolution.
MaxCyte Cell-Engineering Platform Boosts Development Programs of 14 Different Companies
Gaithersburg’s MaxCyte Signs Clinical and Commercial License with Seattle’s Sana Biotechnology
MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.